Can a pregnancy vaccine shield newborns from RSV? new study investigates

NCT ID NCT07249320

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines how well the ABRYSVO vaccine works when given during pregnancy to prevent RSV in infants. Researchers will compare health outcomes of babies born to vaccinated mothers versus unvaccinated mothers using electronic medical records. The goal is to see if the vaccine reduces RSV-related hospitalizations and other illnesses in the first months of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ABRYSVO (RSV vaccine)
What this could lead to
If successful, this study could confirm that vaccinating pregnant people with ABRYSVO effectively protects their babies from severe RSV disease in the first months of life.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It only includes data from one healthcare system, which may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer

    New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.